Under the terms of the deal, IGI will be responsible for developing two topical drug products, obtaining US Food and Drug Administration (FDA) marketing approvals and commercial manufacture.
Impax will then market and distribute the products through Global Pharmaceuticals, its generics division. Details of the products and terms of the agreement were not disclosed.
Chris Mengler, president of Global Pharmaceuticals, said: "We look forward to working with the experienced team at IGI Laboratories on these two topical drug products.
“This marks our initial entry into alternative dosage forms as we begin to execute our strategy of diversifying our product base.”